3627 results for «345»
3627 results
Seal the deal: echocardioraphy-guided LAA closure for stroke defense
12 Sep 2025 – From PCR Rio Valves 2025
This session focuses on echocardiography-guided left atrial appendage (LAA) closure as a critical strategy for stroke prevention. Attendees will explore optimal cardiac imaging techniques tailored to evolving clinical needs and seasonal considerations. The session also includes comprehensive instruction on post-procedural echocardiographic assessment and post-processing workflows in...
Early outcomes and predictors of success in LATAM TAVI experiences
12 Sep 2025 – From PCR Rio Valves 2025
Explore early outcomes and predictors of success from Latin America's evolving experience with Transcatheter Aortic Valve Implantation (TAVI). This session covers innovative approaches such as transfemoral access intravascular lithotripsy compared to angioplasty, conduction disturbances with self-expandable TAVI devices, and insights from regional centers treating severe aortic...
Out-of-the-box TAVI: when anatomy pushes innovation
12 Sep 2025 – From PCR Rio Valves 2025
Witness innovative TAVI applications pushing procedural boundaries in challenging anatomical scenarios. This session reviews cases including bicuspid valves with septal aneurysm, non-calcific aortic regurgitation with complex aortas, decades-old valve treatments, and novel access strategies in severe peripheral artery disease.
PCR London Valves 2021 – Welcome message
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
Real-world outcomes with the PASCAL Platform in TR
03 Dec 2021
The PASCAL platform, comprising the PASCAL and PASCAL Ace implants, received its CE mark for TR in May 2020 and has been shown to be an effective and safe treatment option for patients with TR.3,4,6 Professor Jörg Hausleiter and Dr Mirjam Wild now describe their single-centre experience...
One-year results of the Clasp TR Study: Transcatheter treatment of tricuspid regurgitation
22 Mar 2022
Alessandro Sticchi and Luigi Biasco provide their take on the 1-year results of the CLASP TR study which were presented by Dr Adan Greenbaum, co-director of the Emory Structural Heart and Valve Center (Atlanta, GA) during the 2022 American College of Cardiology annual Congress held in Washington D.C.
Author
Author
